Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AVT02 vs Humira in Healthy Volunteers
NCT03579823Phase 1Completed
- Sponsor
- Alvotech
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AVT02 in rheumatoid arthritis (RA) and plaque psoriasis (2 arms), sponsored by Alvotech. Primary endpoints: Change from baseline in blood pressure, heart rate, and body temperature at Day 64, Change from baseline electrocardiogram at Day 64 and 4 more. Started May 2018; status: completed.
02
Drugs
AVT02
03
Conditions
rheumatoid arthritis (RA)plaque psoriasis
Beyond the preview
Go deeper on NCT03579823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579823.